FDA approval of mirdametinib for NF1-associated plexiform neurofibromas - clinical and regulatory perspectives

Sep 29, 2026

Uploaded by dawugda

Editorial analyzing the clinical rationale and regulatory framing for FDA approval of mirdametinib in NF1-associated plexiform neurofibromas. The discussion links NF1 pathogenesis to constitutive RAF–MEK–ERK (MAPK) signaling and positions selective MEK1/2 inhibition as a targeted approach for symptomatic, unresectable tumors. It summarizes pharmacology, dosing considerations, safety signals, and approval support from the ReNeu phase IIb trial, highlighting response durability and patient-relevant improvements.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages2

Reading Time5 min

AccessFree to download

Editorial overview

Background on NF1 and plexiform neurofibromas

MEK1/2 inhibition mechanism of mirdametinib

Pharmacokinetics and metabolism

FDA approval and clinical trial evidence (ReNeu phase IIb)

Dosing recommendations and monitoring

Adverse reactions and key safety considerations

Editorial FDA approval of mirdametinib for NF1-associated plexiform neurofibromas: clinical and regulatory perspectives Mahnoor Sheikh, MBBSa , Ehtisham Haider, MBBSb , Noor Un Nisa Irshad, MBBSa , Sakan Binte Imran, MBBSc ,* To the Editor, Neurofibromatosis type 1 (NF1) is an inherited, autosomaldominant disorder resulting from pathogenic variants in the NF1 gene, which encodes neurofibromin, a GTPase-activating protein that normally downregulates RAS signaling [1] . NF1 affects approximately 1 in 2500–3500 individuals worldwide, making it one of the most common inherited tumor syndromes. Clinical manifestations vary widely and include cutaneous findings, skeletal abnormalities, learning difficulties, and multiple benign and occasionally malignant tumors. One of the more serious complications is plexiform neurofibromas (PNs): these tumors develop in up to half of patients, often present early in life, and grow along nerve sheaths in a diffuse and infiltrative pattern, making complete surgical resection difficult and recurrence common. PN can cause pain, neurologic dysfunction, and disfigurement, leading to substantial functional impairment and reduced quality of life[1,2] . Loss of neurofibromin results in constitutive RAS activation, increased cell proliferation, and tumor growth[1] . Advances in the understanding of NF1 pathogenesis, particularly how loss of neurofibromin leads to constitutive RAS–RAF–MEK–ERK (MAPK) pathway activation, have enabled the development of targeted therapies[1] . In this context, mirdametinib has emerged as a mechanism-directed treatment option for symptomatic, unresectable NF1-associated PN[1,2] . Mirdametinib is a potent, selective, non-ATP-competitive inhibitor of MEK1 and MEK2 (mitogen-activated protein kinase 1 and 2, MAP2K1/2) . These kinases are central components of the RAF–MEK–ERK (MAPK/ERK) signaling cascade, which regulates cell proliferation, differentiation, survival, and cellular movement in response to growth factors and stress stimuli. RAS is a small GTPase that acts as a molecular switch and is the master regulator of downstream RAF–MEK–ERK signaling. Clinical aDepartment of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan, bDepartment of Medicine, Punjab Medical College, Faisalabad, Pakistan and cDepartment of Medicine, Sir Salimullah Medical College, Dhaka, Bangladesh Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. *Corresponding author. Address: Department of Medicine, Sir Salimullah Medical College, Dhaka 1100, [Bangladesh. E-mail: sakanbinteimran.ssmc@gmail.com](Bangladesh. E-mail: sakanbinteimran.ssmc@gmail.com) (S.B. Imran). Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and noncommercial, as long as it is passed along unchanged and in whole, with credit to the author. Annals of Medicine & Surgery (2026) 88:22–23 Received 13 October 2025; Accepted 5 November 2025 Published online 18 November 2025 [http://dx.doi.org/10.1097/MS9.0000000000004341](http://dx.doi.org/10.1097/MS9.0000000000004341) studies of mirdametinib demonstrate selective MEK1/2 inhibition and have produced substantial, typically non-cytotoxic reductions in PN volume in both adult and pediatric populations[1] . The peak plasma concentration of mirdametinib is reached approximately 0.8–1.1 h after oral administration, and steady state is typically achieved within ~6 days[3,4] . Mirdametinib is primarily metabolized via glucuronidation (uridine 5’ diphosphoglucoronyltransferase enzymes) and oxidative pathways, with contributions from carboxylesterases, and is eliminated in both urine and feces; following radiolabeled dosing, the majority of radioactivity was recovered in urine. No dosage adjustment is required for mild to moderate

FAQs

Why are plexiform neurofibromas challenging to treat surgically in NF1?

They develop early in life for many patients, grow diffusely along nerve sheaths, and show infiltrative behavior, which makes complete resection difficult and recurrence common.

How does mirdametinib work in NF1-associated plexiform neurofibromas?

Mirdametinib is a selective, non-ATP-competitive inhibitor of MEK1/MEK2, blocking the RAF–MEK–ERK (MAPK/ERK) signaling pathway that is activated downstream of constitutive RAS signaling.

What clinical evidence supported the FDA approval of mirdametinib?

Approval was supported by the pivotal ReNeu phase IIb trial, reporting blinded independent central review-confirmed objective response rates with clinically meaningful improvements in pain and health-related quality of life.

Sep 29, 2026

Uploaded by dawugda